Nagao Satoshi - Tsukuba Research Laboratories, Eisai Co., Ltd

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 23 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

Masatoshi Kudo,Richard S. Finn,Masafumi Ikeda,Max W. Sung,Ari D. Baron,Takuji Okusaka,Masahiro Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Tim Meyer,Satoshi Nagao,Kenichi Saito,Kalgi Mody,Zahra Ramji,Leonid Dubrovsky,Josep M. Llovet

LIVER CANCERno. 4 (2024)

Cited1Views0WOSBibtex

First-Line Lenvatinib Plus Pembrolizumab for Hepatocellular Carcinoma: Post Hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial

Masatoshi Kudo,Masafumi Ikeda,Hiroshi Aikata,Kazushi Numata,Hiroyuki Marusawa,Tetsuya Hosaka,Naoya Kato,Masayuki Kurosaki,Manabu Morimoto,Tatsuya Yamashita,Hironori Koga,Tsutomu Masaki,Naoyoshi Yatsuzuka, Masato Suzuki,Satoshi Nagao,Shuichi Kaneko,Hiromitsu Kumada

LIVER CANCER（2024）

Cited0Views0Bibtex

ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs

MOLECULAR CANCER THERAPEUTICSno. 1 (2023)

Cited3Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn